Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | FES | P07332 | 1/20 | 0.59 |
| ▸ | FER | P16591 | 1/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847443 | 1.00 | EGFR (0.70) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL16515004 | 0.91 | FGFR1 (0.70) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL20787671 | 0.91 | FGFR1 (0.70) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL16513999 | 0.91 | EGFR (0.78) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL29847561 | 0.90 | FGFR1 (0.81) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL16513796 | 0.90 | FGFR1 (0.81) | EGFRFGFR1KDRFGFR2GAK | |
| SCHEMBL16514225 | 0.89 | FGFR1 (0.70) | EGFRFGFR1KDRFGFR2JAK3 | |
| SCHEMBL29847661 | 0.89 | FGFR1 (0.70) | EGFRFGFR1KDRFGFR2JAK3 | |
| SCHEMBL16514731 | 0.88 | FGFR1 (0.67) | EGFRFGFR1KDRFGFR2JAK3 | |
| SCHEMBL16514278 | 0.88 | EGFR (0.71) | EGFRFGFR1KDRFGFR2ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105682661-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2020-03-27 | — | — | CN | claimed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | claimed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | claimed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | claimed |
| EP-3035936-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NeuPharma, Inc. (US) | 2016-06-29 | — | — | EP | claimed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | claimed |
| WO-2015027222-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2015-02-26 | — | — | WO | claimed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3508204-B1 | QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER | NEUPHARMA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-3035936-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NeuPharma, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
| WO-2015027222-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015027222-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | EGFR 518/4885FGFR1 1078/4885KDR 950/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | EGFR 518/4885FGFR1 1078/4885KDR 950/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | EGFR 518/4885FGFR1 1078/4885KDR 950/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | EGFR 272/4885FGFR1 441/4885KDR 1405/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | EGFR 518/4885FGFR1 1078/4885KDR 950/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | EGFR 518/4885FGFR1 1078/4885KDR 950/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | EGFR 290/4885FGFR1 915/4885KDR 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.